Stryker (NYSE:SYK – Get Free Report) had its target price upped by equities research analysts at BTIG Research from $304.00 to $345.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical technology company’s stock. BTIG Research‘s price objective would suggest a potential upside of 8.76% from the company’s current price.
Other equities analysts also recently issued research reports about the company. Stifel Nicolaus dropped their price target on Stryker from $330.00 to $325.00 and set a “buy” rating on the stock in a research report on Monday, November 2nd. Canaccord Genuity Group downgraded Stryker from a “buy” rating to a “hold” rating and decreased their price objective for the company from $385.00 to $300.00 in a report on Friday, October 30th. Raymond James Financial reaffirmed an “outperform” rating and issued a $323.00 price objective (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Piper Sandler raised their target price on shares of Stryker from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Monday, November 9th. Finally, Jefferies Financial Group reduced their price target on shares of Stryker from $440.00 to $405.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Twenty-one research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $343.77.
Get Our Latest Analysis on SYK
Stryker Stock Performance
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. During the same quarter in the previous year, the firm posted $3.19 EPS. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. As a group, equities analysts predict that Stryker will post 14.85 EPS for the current year.
Insiders Place Their Bets
In related news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the transaction, the director owned 1,701,375 shares in the company, valued at $553,491,315. This trade represents a 24.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.60% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Gables Capital Management Inc. acquired a new stake in Stryker in the second quarter valued at approximately $25,000. Kilter Group LLC acquired a new position in shares of Stryker during the second quarter worth $25,000. Cornerstone Financial Management LLC lifted its holdings in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Highland Investment Advisors LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $25,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Stryker in the 2nd quarter worth $27,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Read More
- Five stocks we like better than Stryker
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
